Abstract 2911
Background
EGFR-TKI have been widely used in patients (pts) with EGFR mutations in NSCLC and brought significant benefits. But resistance to EGFR-TKI is inevitable. Previous studies have shown that apatinib (a TKI against VEGFR-2) combined with EGFR-TKI might prevent progression of the disease. We conducted this trial to investigate the efficacy and safety of apatinib combined with EGFR-TKIs (including erlotinib, gefitinib, icotinib, afatinib and osimertinib) compared with traditional chemotherapy for EGFR-TKI-resistant NSCLC pts.
Methods
This study enrolled 39 advanced NSCLC pts who acquired resistance to EGFR-TKI therapy from Mar 2017 to Jan 2019. 25 pts received apatinib combined with EGFR-TKI (apatinib in start dose of 250 mg+prior EGFR-TKI dose),14 pts received chemotherapy (pemetrexed or vinorelbine with platinum).
Results
In the apatinib group, 88% (22/25) pts were available evaluated. The objective response rate was 17% (3/22) and the disease control rate was 96% (21/22). The most common adverse events in the apatinib group were diarrhea (60%,15/25), hypertension (56%,14/25), hand-foot syndrome (40%,10/25), fatigue (30%,7/23). Main grade 3 or 4 toxicities were proteinuria (12%, 3/25). Two pts with brain metastases in the apatinib group showed a decrease of metastatic lesions. The lesions of two pts who having taken the dose of 250mg apatinib and progressed decreased when they changed the dose to 500mg. In the chemotherapy group, 79% (11/14) pts were available to be evaluated. The objective response rate was 27% (3/11) and the disease control rate was 91% (10/11). No new adverse events occurred. The median length of treatment of the apatinib group was 8.7 monthsand of chemotherapy group was 4.3 months. The longest treatment period in the apatinib group was 24 months.
Conclusions
Apatinib combined with EGFR-TKI showed a good clinical efficacy in pts with acquired EGFR-TKI (1st 2nd or 3rd generation) resistance. Patient’s quality of life and the compliance with therapy hads been increased by use of oral drugs. We found that in the patients who were treated with erlotinib, or patients with EGFR 21 mutation, or male, their PFS tended to be prolonged compared to other patients.
Clinical trial identification
ChiCTR-OIN-17012051.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
China Anti-Cancer Association.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract